Skip to content
Impact Report
Fellow
Anu Balaji

Anu Balaji

AlcoChange
AlcoChange is a regulated digital therapeutic that supports people with alcohol problems through app-based behavioural interventions, remote management, and clinical dashboards.

Anu Balaji is the Product Head at CyberLiver, where he leads the development, NHS and Private sector adoption of AlcoChange — a regulated digital therapeutic for people affected by alcohol harm. Over the past 10 years, he has collaborated with clinicians, researchers, patients, and frontline staff in getting AlcoChange from early concept through NIHR-funded clinical research to real-world deployment with the NHS and private healthcare providers.

Under his leadership, AlcoChange achieved MHRA UKCA Class IIa certification, ISO 13485 and DTAC compliance, and has been evaluated across 25 NHS hospitals as part of a multicentre randomised controlled trial. The platform is now in paid use at Royal Aberdeen Hospital and the Priory Group, supporting patients through digital monitoring, behavioural interventions, and clinician-facing dashboards.

Anu has co-authored peer-reviewed research published in JHEP Reports and presented at national and international hepatology and digital health conferences. He has worked directly with Alcohol Liaison Teams, NIHR, and community partners to understand adoption barriers and design solutions that fit within existing NHS workflows.

He is committed to bridging the gap between hospital and community alcohol care, with a focus on reaching underserved populations through accessible, stigma-free digital tools.